Tier 2 — strong

SIRT6 in Cancer: Mechanistic Insights into Its Dual Roles in Cancer Biology and Implications for Precision Therapeutic Development

Yanqi Feng, Zhuoyan Han, Kunrui Zhu, Yuelin Han, Xiangtian Xiao, Jie Tong, Yiming Li, Shu Xia
Biomolecules 2025 15(12):1655

Bibliography

PubMed
PMID 41463311
DOI
10.3390/biom15121655

Study snapshot

DesignNarrative mechanistic and therapeutic review.
ModelPublished cancer, molecular and pharmacology literature.
SampleNot applicable.
InterventionNot applicable.
DurationNot applicable.
EndpointsTumor-suppressive mechanisms; Tumor-promoting mechanisms; DNA repair; Metabolic reprogramming; Epigenetics; SIRT6 modulators

What the study showed, in plain terms

This 2025 review synthesizes why SIRT6 cannot be labeled simply as a tumor suppressor. Depending on tumor type and molecular context, SIRT6 can restrain or support cancer, which means both activators and inhibitors may have therapeutic roles.

Key findings

The review emphasizes context-specific SIRT6 targeting in precision oncology and evaluates small-molecule modulation, genetic interventions and combination strategies.

What this study can and cannot tell us

As a narrative review, it synthesizes heterogeneous preclinical and clinical-association literature and does not itself establish treatment efficacy.

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability